Cardiology Testing
May 12, 2025
Predicting ASCVD With Calprotectin May 12, 2025
Knowing which biomarkers to look for is critical to diagnosing and preventing ASCVD, and a new JAMA study suggests calprotectin could be the key to catching ASCVD early. So how does calprotectin predict ASCVD? To answer this, researchers measured calprotectin levels in plasma collected from 2.4k participants during Phase 2 of the Dallas Heart Study […]
Cardiology Pharmaceuticals
May 8, 2025
Marea Makes Progress on MAR001 May 8, 2025
Marea Therapeutics presented positive data from the Phase 2a clinical trial of its fat-targeting monoclonal antibody, MAR001, that could help address lipid and metabolic drivers of ASCVD. To assess MAR001’s impact on remnant cholesterol and triglycerides, researchers randomized 55 patients with hypertriglyceridemia to one of three doses (150, 300, and 450mg) or placebo and found… […]
Cardiology Pharmaceuticals
May 8, 2025
Obicetrapib Puts on a Show May 8, 2025
Results from NewAmsterdam Pharma’s Phase 3 BROADWAY and TANDEM trials suggest that obicetrapib could be an effective LDL-C lowering treatment, both on its own or combined with another drug. TANDEM examined the effects of a fixed-dose obicetrapib/ezetimibe combination therapy and found… BROADWAY put on a one-man show for obicetrapib as a monotherapy to help confirm […]
